Mar 6th, 2006, 21:39 | 只看该作者 #41 |
Senior Member
注册日期: Jul 2004
帖子: 3,224
|
AVST.OB close 0.014 +311% volume 37M OS 153M ,2005-9-30 Overview. The Company sells a distinctive and highly recognized line of artificial turf products. Such products include natural landscape, safe play area, and putting green materials, driving mats and accessory products. The Company's primary market area is the U.S. and, in particular, those western states where shrinking water supplies are creating an increasing demand for artificial turf products in residential, daycare and commercial landscape applications. The Company's products are distributed primarily to wholesale customers and landscape installation contractors. Perfect Turf, Inc., of which the president of the Company is also the president of its parent company, is acting as the Company's agent on golf and related products in some areas. The Company has and is implementing a plan to acquire and warehouse an inventory of turf products at strategic locations throughout its market territories, but it will need to raise significant additional financing or secure a working capital line of credit in order to successfully fund such expanded operations. If the Company is not able to complete a financing or secure a working capital line of credit in a timely manner, it will need to implement fundamental changes to its business and operations which will likely include substantially reducing, suspending, or terminating such a capacity expansion and substantially reducing its operating expenditures. 因为今天的 PR 讲,将被另一个公司收购,股价长了 311%. 鬼佬网站讲,它每股值 $0.03 - 0.05 http://ragingbull.lycos.com/mboard/b...cgi?board=AVST 我不知道该如何估计他的股价,也不敢碰它。 那位老兄帮助分析一下。 |
|
Mar 6th, 2006, 23:46 | 只看该作者 #43 |
Senior Member
注册日期: Jul 2004
帖子: 3,224
声望: 322403
|
小心 JKRI.OB
close: $0.022 volume 16M +37.5% 以下为缩股纪录: Outstanding Shares: 1,197,324 as of 2005-05-27 Current Capital Change: shs increased by 4 for 1 split. Payable upon surrender Ex-Date: 2005-05-27 Record Date: Pay Date: Dividends: Class Notes: Capital Change=shs decreased by 1 for 1000 split. Pay date=11-22-04 Capital Change=shs decreased by 1 for 2000 split. Pay date=2-1-05 Capital Change=shs decreased by 1 for 2000 split. Pay date=5-9-05 纯粹是骗子公司,他的伎俩就是缩股,把所有投资者的血吸干。!, 象这种股票,小心为好,否则,可能会死的很惨! |
|
Mar 6th, 2006, 23:57 | 只看该作者 #44 |
Senior Member
注册日期: Jul 2004
帖子: 3,224
声望: 322403
|
一路货 PCCE.OB
骗子公司 close: $0.0004 +33% volume 2.49B Current Capital Change: shs decreased by 1 for 1000 split Ex-Date: Record Date: Pay Date: 2006-01-24 Dividends: Company Notes: Note=1-25-05 State of Incorporation Virginia changed to Nevada Class Notes: Capital Change=shs decreased by 1 for 1000 split. Pay date=10/25/2005. Capital Change=shs decreased by 1 for 100 split. Pay date=04/05/2002. Capital Change=shs decreased by 1 for 4 split. Pay date=10/07/1999. Div. 1 sh The Resourcing Solutions Group, Inc. Com for each sh Com held. Rec date=12-10-02. Pay date=3-7-03 Capital Change=shs decreased by 1 for 30 split. Effective date=3-17-03 Capital Change=shs decreased by 1 for 100 split. Effective date=2-25-04 Capital Change=shs decreased by 1 for 100 split. Effective date=9-13-04 Capital Change=shs decreased by 1 for 1000 split. Pay date=2-25-05 Capital Change=shs decreased by 1 for 1000 split. Effective date=6-20-05 |
|
Mar 7th, 2006, 08:49 | 只看该作者 #47 | |
Senior Member
注册日期: Jul 2004
帖子: 668
声望: 278
|
引用:
我的理解, glif.ob 放量不够 xkem.ob 涨幅已大, 且主力操盘极为老到,凶狠, 经常是向下破位后, 再急拉回来. 此股操作要小心. imnr.ob 非常看好, 稳健的牛股. |
|
|
Mar 8th, 2006, 09:21 | 只看该作者 #54 | |
Senior Member
注册日期: Jul 2004
帖子: 668
声望: 278
|
引用:
问领导个问题, 这种骗子公司, 第一次认购新股时, 大家容易上当. 但屡屡发新股, 那么谁在购买, 后来的新股? |
|
|
Mar 8th, 2006, 11:31 | 只看该作者 #57 |
Senior Member
注册日期: Jul 2004
帖子: 3,224
声望: 322403
|
IMNR.OB 利空
小心了! http://www.pinksheets.com/quote/news...RE&symbol=IMNR The Immune Response Corporation Completes $8 Million Financing CARLSBAD, Calif., Mar 07, 2006 (BUSINESS WIRE) -- The Immune Response Corporation (OTCBB:IMNR) announced today that it has completed a private placement of $8.0 million of secured notes which are convertible into 400,000,000 shares of common stock at $0.02 per share. The secured convertible notes accrue interest at 8% per year and mature on January 1, 2008. Investors also received warrants to purchase an aggregate of 1,200,000,000 shares of common stock at $0.02 per share which have the potential to generate an additional $24 million in gross proceeds. The first tranche of these warrants (600,000,000) expires the later of May 31, 2006, or 45 days following the registration of the shares underlying the warrants. The second tranche of these warrants (600,000,000) become exercisable 70 days after the expiration of the first tranche of the warrants and expire 45 days after they become exercisable. None of these derivative securities will be able to be converted into or exercised for common stock until the Company obtains stockholder approval to significantly increase its authorized number of shares of common stock. "This offering puts us in a much stronger financial position, giving us immediate capital to pursue our business and clinical strategy," said Michael K. Green, Chief Operating Officer and Chief Financial Officer. "More importantly, the $24 million potential additional proceeds from the two tranches of warrant exercises during 2006 could provide us with long-term capital to complete important phase II clinical trials over the next two years." Proceeds from the financing will be used to fund the Company's ongoing and planned clinical activities and for general corporate purposes. Spencer Trask Ventures, Inc., an affiliated entity of two of the Company's directors, served as the exclusive placement agent for the transaction. |
|